Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

en Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA for Contrave or an NDA for Empatic; the therapeutic and commercial value of Contrave or Empatic; Orexigen's ability to maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission August 9, 2012 and which is available from the SEC's website (www.sec.gov) and on Orexigen's website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

 Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491 Orexigen Therapeutics, Inc.Balance Sheets(In thousands, except share and par value amounts)September 30,December 31,20122011(Unaudited)AssetsCurrent assets:Cash and cash equivalents 

$   56,057$  101,749Investment securities, available-for-sale 

52,22745,844Prepaid expenses and other current assets 

1,5071,126Total current assets 

109,791148,719Property and equipment, net 

166439Restricted cash 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... BRIC Gynecological Devices Market Outlook to ... new report, "BRIC Gynecological Devices Market Outlook to ... Gynecological Devices market. The report provides value, in ... average prices (in US dollars) within market segments ... and Mechanical Sterilization Devices (Tubal Clips and Rings)), ...
(Date:9/17/2014)... Sept. 17, 2014 The ambulance ... last decade due to the recession, an ... technological advancements. This BCC Research report analyzes ... of the ambulance and emergency medical services ... and hemorrhage control devices, equipment used for ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 Pomerantz ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NASDAQ: ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... BioPharma and certain of its officers and/or directors have ... Act of 1934.  On September 17, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
(Date:9/17/2014)... 17, 2014 People who struggle to distinguish ... to http://www.perwickstrom.com and get the answer by reading ... point out, is that a business plan and a business ... together, commented Per Wickstrom. “The way I view it is ... business strategy which is part two.” , According to ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Social networking sites can help ... For people who are obese, sites like Twitter and ... support from doctors as well as peers, researchers found. ... methods is that it offers the potential to be ... when compared to traditional approaches," the study,s lead author, ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:North Central Surgical Center Receives Several Accolades 2Health News:New OptiPact™ Technology Introduced by Catalent 2
... ... virtual reality device, the GaitAid, can help stroke patients learn to walk better. , ... Haifa, Israel (PRWEB) February 22, 2010 -- There are ... one of the leading causes of adult disability in the U.S. and Europe., , , , ...
... new survey has found that African-Americans are more likely ... lung cancer, as well as being more reluctant to ... according to researchers from Dana-Farber Cancer Institute and their ... the puzzling racial disparities in lung cancer treatment outcomes ...
... outlets for buying booze increases, so does neighborhood violence, ... The more bars, restaurants and other alcohol sales sites ... say researchers who studied crime statistics and alcohol licensing ... found an association between high assault rates and stores ...
... three million children have been born as a result of ... tube baby" in 1978. While the majority of these ... at greater risk of certain kinds of birth defects and ... and type 2 diabetes later in life. Carmen Sapienza, ...
... types of minimally invasive surgery to repair kidney blockages ... found that robot-assisted surgery was faster and resulted in ... in the Canadian Journal of Urology , Ashok ... Baptist Medical Center, compared laparoscopic and robot-assisted surgery for ...
... 20. "Nanotechnology could aid the future of development of the ... the academy of sciences for the developing world, and president ... at a panel session, "Re-emergence of Science, Technology and Education ... AAAS,s annual meeting in San Diego. "The Arab ...
Cached Medicine News:Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:African-Americans' attitudes about lung cancer may hinder prevention 2Health News:More Bars Equals More Assaults, Study Finds 2Health News:Comparison shows robot-assisted option offers advantages for kidney surgery 2Health News:Nanotechnology could help Arab region 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: